Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8)
DOI: 10.1111/jdv.20688 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 07.04.2025. Verfasst von Giovanni Paolino und 1 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Autor:innen und Institutionen
- Unit of Dermatology, IRCCS Ospedale San Raffaele, Milan, Italy.
- Università Vita-Salute, San Raffaele, Milan, Italy.
- Rare Skin Diseases Center, Istituto Dermopatico Dell'immacolata, IDI-IRCCS, Rome, Italy.
ORCID-Profile: Giovanni Paolino
Zitieren
APA
Paolino, G., & Didona, D. (2025). Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology, 39(8). https://doi.org/10.1111/jdv.20688
Vancouver
Paolino G, Didona D. Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash. Journal of the European Academy of Dermatology and Venereology. 2025;39(8). doi:10.1111/jdv.20688
BibTeX
@article{Paolino2025,
author = {Paolino, Giovanni and Didona, Dario},
title = {Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {8},
doi = {10.1111/jdv.20688}
}
EUVIMED